Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Arovella Therapeutics Limited ( (AU:ALA) ) has issued an announcement.
Arovella Therapeutics Limited has issued 750,000 ordinary shares without disclosure under the Corporations Act, complying with relevant legal provisions. This move is part of their ongoing efforts to strengthen their financial position and support their innovative cancer treatment developments, potentially enhancing their market presence and offering new opportunities for stakeholders.
More about Arovella Therapeutics Limited
Arovella Therapeutics Ltd is a biotechnology company specializing in developing invariant natural killer T (iNKT) cell therapy to treat blood cancers and solid tumors. Their lead product, ALA-101, utilizes CAR19-iNKT cells targeting CD19 and CD1d antigens found on various cancer types. The company is also advancing solid tumor treatments with CLDN18.2-targeting technology and IL-12-TM technology.
Average Trading Volume: 2,307,759
Technical Sentiment Signal: Sell
Current Market Cap: A$113.7M
See more data about ALA stock on TipRanks’ Stock Analysis page.